255 related articles for article (PubMed ID: 18250496)
21. [Present concepts of congenital long QT syndrome].
Leenhardt A; Denjoy I; Maison-Blanche P; Guicheney P; Coumel P
Arch Mal Coeur Vaiss; 2000 Apr; 93(3 Spec No):17-21. PubMed ID: 10816797
[TBL] [Abstract][Full Text] [Related]
22. QT interval prolongation and torsade de pointes.
Patanè S; Marte F; Di Bella G
Int J Cardiol; 2009 Jan; 131(2):e51-3. PubMed ID: 17689729
[TBL] [Abstract][Full Text] [Related]
23. [Current classification of anti-arrhythmia agents].
Weirich J; Wenzel W
Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs.
Vieweg WV
J Clin Psychiatry; 2002; 63 Suppl 9():18-24. PubMed ID: 12088172
[TBL] [Abstract][Full Text] [Related]
25. Torsades de pointes with methadone.
Prescrire Int; 2005 Apr; 14(76):61-2. PubMed ID: 15875343
[TBL] [Abstract][Full Text] [Related]
26. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.
Ehret GB; Voide C; Gex-Fabry M; Chabert J; Shah D; Broers B; Piguet V; Musset T; Gaspoz JM; Perrier A; Dayer P; Desmeules JA
Arch Intern Med; 2006 Jun; 166(12):1280-7. PubMed ID: 16801510
[TBL] [Abstract][Full Text] [Related]
27. Drug-induced q-T prolongation.
Kao LW; Furbee RB
Med Clin North Am; 2005 Nov; 89(6):1125-44, x. PubMed ID: 16227057
[TBL] [Abstract][Full Text] [Related]
28. Neonatal long QT syndrome due to a de novo dominant negative hERG mutation.
Beery TA; Shooner KA; Benson DW
Am J Crit Care; 2007 Jul; 16(4):416, 412-5. PubMed ID: 17595376
[TBL] [Abstract][Full Text] [Related]
29. Cetirizine and loratadine: minimal risk of QT prolongation.
Prescrire Int; 2010 Feb; 19(105):26-8. PubMed ID: 20455340
[TBL] [Abstract][Full Text] [Related]
30. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
Shantsila E; Watson T; Lip GY
Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
[TBL] [Abstract][Full Text] [Related]
31. [The long QT interval syndrome].
Heinc P
Vnitr Lek; 2003 Oct; 49(10):813-9. PubMed ID: 14682155
[TBL] [Abstract][Full Text] [Related]
32. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
33. Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.
Calderone V; Testai L; Martinotti E; Del Tacca M; Breschi MC
J Pharm Pharmacol; 2005 Feb; 57(2):151-61. PubMed ID: 15720777
[TBL] [Abstract][Full Text] [Related]
34. Novel therapeutics for treatment of long-QT syndrome and torsade de pointes.
Khan IA; Gowda RM
Int J Cardiol; 2004 May; 95(1):1-6. PubMed ID: 15159030
[TBL] [Abstract][Full Text] [Related]
35. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
[TBL] [Abstract][Full Text] [Related]
36. [New perspectives in long QT syndrome].
Medeiros-Domingo A; Iturralde-Torres P; Canizales-Quinteros S; Hernández-Cruz A; Tusié-Luna MT
Rev Invest Clin; 2007; 59(1):57-72. PubMed ID: 17569301
[TBL] [Abstract][Full Text] [Related]
37. Torsades de pointes with a severely prolonged QT interval induced by an initial low dose sotalol intake.
Yalta K; Turgut O; Yilmaz A; Yilmaz MB; Kendirlioglu O; Karadas F
Int J Cardiol; 2007 Apr; 116(3):e95-7. PubMed ID: 17126428
[TBL] [Abstract][Full Text] [Related]
38. Anaesthetics and the rate corrected interval: learning from droperidol?
Shipton EA
Curr Opin Anaesthesiol; 2005 Aug; 18(4):419-23. PubMed ID: 16534268
[TBL] [Abstract][Full Text] [Related]
39. Takotsubo cardiomyopathy as a potential cause of long QT syndrome and torsades de pointes.
Ghosh S; Apte P; Maroz N; Broor A; Zeineh N; Khan IA
Int J Cardiol; 2009 Aug; 136(2):225-7. PubMed ID: 18617280
[TBL] [Abstract][Full Text] [Related]
40. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
